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A B S T R A C T
This articles serves as a guide to using cost-effectiveness analysis
(CEA) to address health equity concerns. We ﬁrst introduce the
"equity impact plane," a tool for considering trade-offs between
improving total health—the objective underpinning conventional
CEA—and equity objectives, such as reducing social inequality in
health or prioritizing the severely ill. Improving total health may
clash with reducing social inequality in health, for example, when
effective delivery of services to disadvantaged communities requires
additional costs. Who gains and who loses from a cost-increasing
health program depends on differences among people in terms of
health risks, uptake, quality, adherence, capacity to beneﬁt, and—
crucially—who bears the opportunity costs of diverting scarce
resources from other uses. We describe two main ways of using
CEA to address health equity concerns: 1) equity impact analysis,
which quantiﬁes the distribution of costs and effects by equity-
relevant variables, such as socioeconomic status, location, ethnicity,
sex, and severity of illness; and 2) equity trade-off analysis, which
quantiﬁes trade-offs between improving total health and other
equity objectives. One way to analyze equity trade-offs is to count
the cost of fairer but less cost-effective options in terms of health
forgone. Another method is to explore how much concern for equity
is required to choose fairer but less cost-effective options using
equity weights or parameters. We hope this article will help the
health technology assessment community navigate the practical
options now available for conducting equity-informative CEA that
gives policymakers a better understanding of equity impacts and
trade-offs.
Keywords: cost-effectiveness analysis, delivery of health care, health
equity, technology assessment.
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Introduction
Health equity has risen to prominence on policy agendas in the
wake of the universal health coverage movement [1–3] and
landmark international reports on inequality in health [4,5] and
health care [3,6,7]. The cost-effectiveness analysis (CEA) studies
that are routinely used around the globe to inform priority setting
in health care and public health, however, rarely provide infor-
mation about who gains and who loses from health programs or
about trade-offs between cost-effectiveness and equity in the
distribution of health-related outcomes [8–12].
In recent years there have been a number of methodological
advances in this area, which have been developed into practical
tools, including extended cost-effectiveness analysis and distri-
butional cost-effectiveness analysis [13,14]. This article describes
those tools and uses illustrations from high-, middle-, and low-
income countries to demonstrate how they can be used to
generate useful new information for decision makers about
health equity impacts and trade-offs. In so doing, we part
company from a venerable school of thought in public ﬁnance,
according to which economic analyses of speciﬁc public expen-
diture programs and regulations should focus on potential Pareto
efﬁciency in the sense of the Hicks-Kaldor compensation test and
leave equity as a matter for income redistribution through the
general taxation and social security system [15,16].
Implicitly or explicitly, all CEA studies already incorporate
social value judgments about equity—for example, in scoping
and methodologic decisions about the relevant policy options
and comparators, which costs and effects to measure, how to
compare costs and effects of different kinds, how to aggregate
costs and effects for different people and organizations, how to
value future costs and effects, and so on [17]. These value
judgments are rarely mentioned in applied CEA studies or health
technology assessment (HTA) reports but are extensively dis-
cussed in textbooks, methods guidance documents, and other
underpinning literature [18]. This article shows how to go beyond
this standard approach of incorporating prespeciﬁed value judg-
ments about equity within applied CEA studies, moving instead
toward using CEA techniques to generate new information about
the health equity implications of alternative policy options that
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facilitate deliberation among decision makers and stakeholders
[8,18]. Equity-informative economic evaluation is an input into
decision-making processes, not an algorithm for determining
decision outcomes [18]. The appropriate weight to give equity
considerations in a particular decision is not a matter for analysts
to resolve, but something for decision makers to consider in
consultation with stakeholders.
We focus on two general categories of policy concern for
health equity, which can both be used to address a wide range of
more speciﬁc concerns: 1) reducing social inequalities in health
and ﬁnancial protection from ill-health; and 2) prioritizing the
severely ill. Within the ﬁrst category, our illustrative examples
focus mainly on distributional impacts according to socioeco-
nomic, ethnic, and sex groups, although the methods described
are applicable to other differences in health-related outcomes
that policymakers may consider unfair, including differences by
geographical location, disability, mental illness, and other social
variables.
First, we introduce two key concepts that underpin the
economic approach to health equity analysis: 1) health equity
trade-offs and 2) net equity impact. We then describe two
approaches to conducting equity-informative CEA: 1) equity
impact analysis, which quantiﬁes the distribution of costs and
effects by equity-relevant variables; and 2) equity trade-off
analysis, which quantiﬁes trade-offs between improving total
health and other equity objectives.
Health Equity Trade-offs
The policy objective underpinning conventional CEA can be
thought of as a health equity objective: the quasi-utilitarian
objective of maximizing total health in the general population
[19,20]. CEA compares the costs and effects of two or more
mutually exclusive policy options [21]. To facilitate comparison
between policies in different disease areas with diverse and
distinct mortality and morbidity impacts, health effects are often
measured using a composite summary index of health, such as
the quality-adjusted life-year (QALY) or the disability-adjusted
life-year (DALY). This allows the comparative effectiveness of
programs to be assessed in terms of both individual and
population-level health.
Population-level health gain is simply the unweighted sum
total of all individual health gains, based on the standard value
judgment that “a QALY is a QALY.” This also allows the calcu-
lation of an incremental cost per QALY gained, or per DALY
averted, of one policy option compared with another. A cost-
increasing policy option can be considered cost-effective if its
cost per unit of health gain compares favorably with alternative
ways of using resources. This recognition of opportunity costs—
that resources used in the provision of a program would have
generated value if used elsewhere—is fundamental to CEA.
Every beneﬁt attributed to a program must be assessed
relative to those displaced when resources are diverted from
alternative activities. In a public health system with a ﬁxed
budget, the displaced activities will comprise alternative health
programs that would have produced alternative health beneﬁts.
Cost-effectiveness can then be deﬁned as a test of whether a
program will improve total health. A cost-effective policy will
have a positive net health impact because its health gains will
outweigh the health losses that result from shifting expenditure
away from other health programs. By contrast, a cost-ineffective
policy will have a negative net health impact because the health
losses that result from shifting expenditure away from other
health programs will outweigh the health gains.
CEA can thus help decision makers to choose cost-effective
investments that increase total health and avoid cost-ineffective
investments that reduce total health. This interpretation of
opportunity costs in terms of forgone health beneﬁts is more
problematic if there is no ﬁxed health budget. Opportunity costs
then may fall instead on household consumption (via increased
taxes or insurance premiums) or on reductions in public expen-
diture on programs not primarily designed to improve health.
Regardless, thinking about trade-offs between cost-effectiveness
and health equity is useful even if the test of cost-effectiveness,
or value for money, is not interpreted in terms of health
maximization.
The health equity impact plane in Figure 1 is a simple way of
thinking about the potential trade-offs between cost-
effectiveness and an alternative health equity objective, such as
reducing inequality in lifetime health or giving priority to those
who are currently severely ill. The vertical axis shows the cost-
effectiveness of a health program. As explained, it is often useful
to think of cost-effectiveness as a measure of net total health
impact: the total health beneﬁts of the program minus the
forgone health beneﬁts that would have been obtained by
spending the same money on other health programs.
The horizontal axis shows the net health equity impact of the
program. This refers to the net impact on the alternative health
equity objective, again after allowing for program opportunity
costs as well as program beneﬁts [21]. The net equity impact may
be assessed informally by the decision maker in light of disag-
gregated information or by using formal health equity metrics
that combine disaggregated information in a summary index
[22,23]. Different equity metrics can yield different conclusions,
and the choice of metric requires justiﬁcation based on explicit
value judgments about a number of difﬁcult conceptual ques-
tions, including equality of what? (e.g., outcome or opportunity),
equality between whom? (e.g., all individuals or particular social
groups), and equality indexed how? (e.g., absolute or relative
indices) [24,25]. In practice, the choice of metric will often reﬂect
pragmatic considerations of data availability as well as value
judgments—for example, because opportunity is hard to meas-
ure, health outcomes may sometimes be a useful proxy indicator
for impacts on health opportunities [26].
In Figure 1, a policy that falls in quadrant I improves both total
health and equity (“win-win”); in quadrant III, the policy harms
both (“lose-lose”). In these two cases, the impacts on health
maximization and health equity are in the same direction, so
trade-offs are irrelevant. In contrast, in the other two quadrants,
impacts on health maximization and equity are opposed and
trade-offs become relevant. In quadrant II, the policy is good for
total health but bad for equity (“win-lose”), and in quadrant IV,
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Fig. 1 – Health equity impact plane.
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the policy is bad for total health but good for equity (“lose-win”).
If all policies fell in quadrants I and III (“win-win” and “lose-
lose”), there would be no need to analyze health equity impacts.
The policy identiﬁed as cost-effective using standard CEA would
always improve health equity, and a cost-ineffective policy would
always harm health equity.
Many policies do indeed fall into quadrants I and III. In low-
and middle-income countries, for example, investments in high-
cost hospital treatments may fall into the “lose-lose” quadrant of
being neither cost-effective nor likely to improve health equity
insofar as they deliver small health gains per unit of cost and
disproportionately beneﬁt well-off groups [27]. In contrast, vacci-
nation programs (e.g., rotavirus immunization [28]) and infec-
tious disease control programs (e.g., tuberculosis [13]) may fall
into the “win-win” quadrant of delivering large health gains per
unit cost and reducing health inequity insofar as they dispro-
portionately beneﬁt socially disadvantaged groups.
In some cases, however, socially disadvantaged groups may
gain less than advantaged groups from a decision to fund a
particular medical technology as a result of factors such as
unequal access to or quality of health care. As a case in point,
access costs may be relatively high and health care coverage
relatively low in remote, rural areas that lack well-resourced
health facilities. In such cases, there may be trade-offs between
cost-effectiveness and health equity. Policy makers may wish to
consider redesigning delivery strategies to increase utilization
and quality in disadvantaged communities, and may even wish
to consider equity-oriented strategies that are less cost-effective
than standard delivery strategies and lie in the “lose-win”
quadrant.
Equity trade-offs can also arise in relation to preventive health
interventions that seek to change behavior—including participa-
tion in screening and vaccination campaigns, as well as changes
in smoking, diet, physical exercise, and other lifestyle behaviors
—insofar as it may be more challenging and costly to change
behavior in relatively disadvantaged communities, so preventive
interventions may have more success in improving health in
advantaged communities [29–31]. Such circumstances can give
rise to preventive public health programs that lie in the “win-
lose” quadrant (cost-effective but harmful to health equity), a
phenomenon sometimes referred to as intervention-generated
inequality [29].
This health equity impact plane provides a simple illustration
for understanding when trade-offs are necessary. It can also be
operationalized to present this information to decision makers,
which has been done in two recent examples from the United
Kingdom [32,33].
Net Equity Impacts
When assessing equity impacts, both the distribution of beneﬁts
and the distribution of opportunity costs are important. The
forgone health beneﬁts that could have been generated through
the next-best alternative may be unequally distributed, and this
distribution is required to estimate the net distributional health
impact of a program [34]. The distribution of opportunity costs
will depend crucially on how a program is funded. For example, if
a program is funded by increasing general, progressive taxation,
the absolute ﬁnancial costs will be borne disproportionately by
the rich, although the opportunity costs in terms of losses in
health and well-being may be more equally distributed. In
contrast, if a program is funded by reducing public expenditure
on other health, education, or welfare services, the opportunity
costs in terms of losses in health and well-being may be borne
disproportionately by poorer individuals who rely more heavily
on public services. The same applies to foreign aid funding that
would otherwise be used to fund alternative programs that
disproportionately beneﬁt more socially disadvantaged people.
The potential health equity implications of alternative sources
of funding are illustrated in Figure 2. The “gross” health impacts
consider only the distribution of program beneﬁts, as if there
were no health opportunity costs. These gross impacts are shown
as the upper circles in the diagram, representing the sum total
population health gains due to the program (e.g., in QALYs or
DALYs). For example, if one were evaluating a breast cancer
detection program, the gross impacts are the health gains due to
the increase in cases of early detection of breast cancer and
subsequent gains in length and quality of life for those patients
that result from treatment at an early stage. The downward
arrows then convert these gross health impacts into “net” health
impacts, accounting for the distribution of health opportunity
costs due to diverting resources from other uses. Case 1 illus-
trates a case in which the health opportunity costs are assumed
to be equally distributed. Case 2 illustrates a case in which
funding comes from a program that disproportionately beneﬁts
socially disadvantaged groups. Case 2 shows that programs that
may initially seem to have a pro-poor health equity impact may
in fact be equity neutral or even anti-poor when one accounts for
the health effects of diverting money from alternative uses.
Equity Impact Analysis
Cost-effectiveness analysis can be used to examine the distribu-
tion of beneﬁts and opportunity costs from alternative policy
options, broken down by one or more variables of concern to
policymakers from an equity perspective. At the request of the
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UK health minister, for example, Holmes et al. [35] used CEA to
model the social class distribution of the impacts of minimum
alcohol pricing in the United Kingdom. They examined the effects
on alcohol consumption, spending, and alcohol-related health
harm and found that health beneﬁts are substantially concen-
trated on heavy drinkers in routine and manual worker
households.
Extended Cost-Effectiveness Analysis
In low- and middle-income countries, a common approach to
equity impact analysis is extended CEA (ECEA), developed by the
Disease Control Priorities, third edition (DCP-3) project (http://www.
dcp-3.org) [36]. ECEA analyzes the distribution of both health
beneﬁts and ﬁnancial risk protection beneﬁts (prevention of
illness-related impoverishment) per dollar expenditure on spe-
ciﬁc policies in a given country. ECEA examines the ﬁnancial risk
protection beneﬁts of policies given the high incidence of out-of-
pocket payments in a large number of low- and middle-income
countries and because the prevention of medical impoverish-
ment is one major objective of health systems and universal
health coverage [37].
As an illustration of ECEA, Verguet et al. [38] examined the
distributional impact of a 50% cigarette price increase through
excise tax in China over a 50-year period, compared to no change.
They found that such excise tax increases could be pro-poor in
China: the years of life gained would be more concentrated on the
poor (79 million in the poorest quintile group) than on the rich (11
million in the richest quintile group), and the ﬁnancial risk
protection beneﬁts would be largely concentrated among the
poorest quintile group (accruing about 70% of the total $2 billion
of insurance value gained).
ECEA has now been applied to the study of about 20 policy
interventions in different low- and middle-income countries,
producing breakdowns of costs, health beneﬁts, and ﬁnancial
risk protection beneﬁts by socioeconomic quintile group [39].
Hitherto, such analyses have tended to focus on distributions
by socioeconomic group, but other equity-relevant variables can
also be examined, including geographical location, ethnicity, sex,
and severity of illness [40,41].
Distributional Cost-Effectiveness Analysis
Another framework for equity impact analysis is distributional
CEA (DCEA), developed by the University of York. This approach
focuses on the distribution of health effects and pays careful
attention to the distribution of health opportunity costs from
displaced expenditure within a ﬁxed health care budget. Asaria
et al. [14] used DCEA to examine the distributional health
impacts, by social deprivation, ethnicity, and sex, of targeted
versus universal reminder strategies for increasing uptake of
bowel cancer screening. They found that the targeted strategy
delivered a smaller gain in total health but a larger reduction in
health inequality [23].
DCEA allows multiple inequality impacts on different social
groups to be combined in the same analysis and compared in
magnitude. It also aggregates all costs and effects into the
common metric of net health beneﬁts as well as presenting
ﬁndings in a disaggregated form. This allows the construction
of summary measures of net health equity impact that can be
plotted on the horizontal axis of the equity impact plane, rather
than reliance on judgments based on disaggregated data on the
distribution of costs and effects. If required, this equity impact
metric can then be weighed against the cost-effectiveness metric
(net health beneﬁt) on the vertical axis using an overall equity-
weighted index of social welfare that combines concern for both
equity and cost-effectiveness. As discussed later, we do not
propose using an index of this kind as an all-purpose algorithm
for decision making. Rather, we recommend sensitivity analysis
using different equity weights to explore the implications of
alternative views about the appropriate trade-offs between
improving total health and reducing health inequity. A limitation
of DCEA is that, like conventional CEA, it does not examine
effects on ﬁnancial risk protection. However, this limitation may
be less important in countries like the United Kingdom where few
people suffer impoverishment as a result of medical costs [42].
Equity impact analysis can also be conducted outside the
context of CEA and the aforementioned ECEA and DCEA frame-
works. Bajekal et al. [43] examined the distributional impact of
changes in risk factors and treatment utilization on coronary
heart disease mortality in different social groups in England from
2000 to 2007. This kind of study does not directly inform the
priority-setting task of selecting among speciﬁc policies, how-
ever, because it does not provide information about the costs and
effects of policies on changing risk factors or treatment
utilization.
Another form of distributional impact analysis that is typi-
cally conducted outside the context of CEA is known as beneﬁt-
incidence analysis. This analysis looks at the beneﬁts of public
health care spending as a whole for different social groups. It
generally examines only health care consumption and coverage
rather than health outcomes, and looks at the average beneﬁts of
current expenditure rather than the marginal beneﬁts of poten-
tial future changes in expenditure. Some recent beneﬁt incidence
analyses, however, have used data on subnational variation and
change in expenditure and outcomes to estimate the health
outcomes of marginal changes in spending in a way that could
be used more directly to inform priority setting [44].
Equity Trade-Off Analysis
Equity trade-off analysis examines trade-offs between improving
total health and other equity objectives not usually addressed by
CEA. The two main approaches to equity trade-off analysis—
equity-constraint analysis and equity-weighting analysis—are
described below.
Equity Constraint Analysis—Counting the Cost of Equity
A simple approach to equity trade-off analysis is to count the cost
of choosing fairer but less cost-effective options. This can be
thought of as an equity constraint analysis because equity is
treated as a constraint on the pursuit of health-maximizing cost-
effectiveness. For example, Cleary et al. [45] explore the implica-
tions of imposing the equity constraint to treat either 100% of
eligible patients or none. This can be seen as an equity constraint
insofar as it avoids creating a “two-tier” public service that
delivers effective treatment to some patients but not others.
Cleary et al. [45] explore the total health implications of
imposing versus relaxing this equity constraint regarding indivi-
sibility of health program delivery in relation to anti-retroviral
therapy (ART) for human immunodeﬁciency virus (HIV). For
example, in their Table VI, they ﬁnd that with a budget of $6–$8
billion dollars, this equity constraint would drive the choice of no
ART, even though less than 100% provision of ﬁrst-line ART
would be more cost-effective and deliver more total health. With
a budget of $12 billion, indivisibility prevents the funds from
being used to provide second-line ART to less than 100% of the
eligible population, which would also deliver more total health.
The health loss associated with choosing the more “equitable”
option gives an indication of the value the decision maker places
on this equity constraint [11]. This approach can be implemented
either by using a simple cost-effectiveness framework that
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compares two or more options given a ﬁxed budget or by using
more specialized mathematical programming techniques to han-
dle complex choices involving different amounts of expenditure
on different programs [10,41,46,47].
Equity-Weighting Analysis—Valuing the Importance of
Equity
When programs fall in the “win-lose” or “lose-win” quadrants of
the health equity impact plane, decision makers face difﬁcult
trade-offs between equity and cost-effectiveness. Equity-
weighting analysis can be used to help policy-makers assess
these trade-offs by quantifying how much concern for equity is
required to choose cost-ineffective options that improve equity
(programs in the “lose-win” quadrant) and cost-effective options
that harm equity (programs in the “win-lose” quadrant). This can
be done using “equity weights” for health beneﬁts that apply to
people with different characteristics or using an “equity param-
eter” that quantiﬁes the degree of concern for reducing health
inequity versus improving total health.
Different characteristics of health policies and the people affected
by them can be used as the basis for setting equity weights, and
several different equity-weighting systems have been proposed
[48,49]. Many of these systems do not pay special attention to the
social characteristics of people but rather focus on their health
characteristics—in particular, current severity of illness or overall
lifetime experience of health, including past, present, and future
health [50–55]. These systems tend to be based on one or more
equity parameters, such as an inequality aversion parameter within
a social welfare function, which speciﬁes how much one cares about
reducing unfair health inequality but does not directly specify how
much one cares about individuals with certain social characteristics
[23,56]. An equity parameter does, however, indirectly imply a
speciﬁc set of equity weights for people with different characteristics
when combined with information about the existing distribution of
health among individuals with those characteristics. These implied
weights will then change in response to changes in the distribution
of health and social variables.
Equity-weighting analysis also requires that all costs and effects
be aggregated into a common metric to which weights can be
applied, such as annual mortality risk, life years, QALYs, or DALYs.
In addition, if decision makers are interested in impacts on relative
inequality (e.g., life expectancy ratios) as well as absolute inequality
(e.g., life expectancy gaps), then an estimate of the baseline distri-
bution of health will be required because relative inequality impacts
depend on the baseline levels as well as the absolute changes.
Discussion
In response to growing policy concerns about health equity, the tools
of economic evaluation are being refashioned to provide useful
evidence about health equity impacts and trade-offs. This article
has introduced the key concepts that underpin the use of CEA to
address health equity concerns. This article has also reviewed the
main practical tools available for analyzing who gains and who loses
from policy interventions (equity impact analysis) and for assessing
equity trade-offs between improving total health and other health
equity objectives not usually addressed by CEA (equity trade-off
analysis). These approaches can also be thought of as a type of
multicriteria decision analysis with two decision criteria—improving
total health and improving health equity—and could be embedded
within a wider multicriteria decision analysis that encompasses
further decision criteria [57,58].
The methods we describe can be used to address most but not
all of the equity concerns that routinely arise in HTA, including 1)
concern for reducing inequalities in health-related outcomes by
income, ethnicity, geographical location, disability, sex, and other
social variables; and 2) concern for prioritizing severely ill
patients, including “end-of-life” patients. “Fair innings”–type
concerns to reduce lifetime inequalities can be addressed under
both headings 1) and 2) by using lifetime health metrics. These
methods, however, do not address other issues sometimes
discussed in relation to equity (e.g., orphan diseases, productivity
costs, beneﬁts to careers, and nondiscrimination) and have not
yet been extended to analysis of inequality between current and
future generations or the dynamics of social mobility [59].
Aligning the methods of CEA to address equity concerns is
only one facet of the much larger question of how to design fair
processes of decision making that appropriately address equity
concerns [8,18]. Equity-informative CEA can only address a subset
of the diverse stakeholder concerns about fairness that may arise
in relation to a speciﬁc decision, and decision makers will always
need to consider wider issues and using further sources of
information. One useful approach to ensuring that decision
makers give due attention to wider equity concerns, for example,
is the use of equity checklists [59–61].
More fundamentally, robust institutional structures, proc-
esses, and incentives are needed to ensure that decision makers
take appropriate steps to reduce inequities in health. Analysis of
the health equity implications of decisions cannot help to
improve decision making if, for example, the analysis is poorly
conducted or communicated, or based on the idiosyncratic value
judgments of a narrow group of experts rather than the broader
community of stakeholders, if policy advisers lack sufﬁcient
training to understand the ﬁndings, or if the conclusions are
disregarded by decision makers who merely pay lip-service to
health equity concerns.
Using CEA to analyze equity impacts and trade-offs requires
the same basic analytical skills needed for standard CEA. It is
more demanding, however, in terms of data requirements
because it requires social distributions of key parameters rather
than population average values. Data limitations can be partic-
ularly severe in low-income countries that lack basic health
information systems, such as vital statistics on births and deaths
and hospital and primary care administrative data. As the DCP3
project has amply demonstrated, however, equity-informative
CEA can successfully be performed in low- and middle-income
countries using existing survey-based data sets, such as the
demographic and health surveys, which include information
disaggregated by socioeconomic status and geographical setting.
An important frontier for future research is to provide better
estimates of the distribution of opportunity costs. Work is
ongoing to examine this distribution in England, drawing on
existing research on variation in health expenditure and out-
comes at a subnational level [62]. Linking this research with data
on health care utilization by different social groups will provide
empirical estimates of how the opportunity costs of health
expenditure within a ﬁxed health budget are distributed. This
also opens the prospect of producing “equity league tables” by
ICD-10 disease code to provide decision makers with a rough
indication of the likely health equity impacts of programs in
particular disease areas, without the need to undertake a full-
blown equity impact analysis. This work is challenging, however,
because many countries do not have suitable subnational data on
variation in health expenditure and outcomes or may have
health system characteristics that make it difﬁcult to identify
where the opportunity costs lie.
In the past, some authors have taken a skeptical view of the
value of equity-weighting analysis due to the difﬁculty of secur-
ing consensus on an equity “algorithm” or “tariff” that rigidly
prespeciﬁes particular equity weights—for example, differential
weights for individual health gains according to disease type (e.g.,
cancer), health characteristics (e.g., severity) or social
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characteristics (e.g., being poor) [63]. Equity-weighting analysis,
however, does not have to be used as an algorithm for making
decisions. Instead, we recommend that it be used as an aid to
deliberation in the context of a speciﬁc decision via sensitivity
analysis of different equity parameters to help decision makers
and stakeholders explore the implications of alternative value
judgements about equity. An advantage of this approach is that it
helps to clarify the equity arguments advanced by different
parties by laying bare their logical implications. The reporting
of sensitivity analyses using different equity parameters may
also help form useful “equity benchmarks” for decision makers to
compare across different decisions.
Thus, we do see a role for equity-weighting sensitivity
analysis as an aid to deliberation in the context of speciﬁc
decisions in light of information on who gains and who loses.
For example, the Dutch use sensitivity analysis around severity
weighting in the economic evaluation evidence used to support
decisions on inclusion in their basic health beneﬁts package [64].
The UK National Institute for Health and Care Excellence uses
sensitivity analysis on the narrower concept of “end-of-life”
weights [65]. We also see a potential role for simple, pragmatic
guidance on appropriate equity benchmarks that decision mak-
ers in particular jurisdictions may wish to recommend after an
appropriate process of public consultation. For example, in 2014,
the third Norwegian Committee on Priority Setting in the Health
Sector proposed a way of distinguishing three categories of
disease severity together with guidance on differential cost-
effectiveness threshold ranges for these different categories [53].
Unlike the methods of severity weighting, the methods of ECEA
and DCEA for analyzing who gains and who loses from decisions
are not yet widely known among the HTA community and are not
yet widely used to inform decision making. These methods are
now starting to be applied, however, and are gradually becoming
more sophisticated [66]. We therefore hope this article will help
the HTA community to navigate the practical options open to
them for providing policy makers with more useful information
about the health equity implications of their decisions.
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